Literature DB >> 26400284

Association between angiogenic growth factor genetic polymorphisms and the risk of osteosarcoma.

H F Zhang1, J P Yan1, Y S Zhuang1, G Q Han1.   

Abstract

The aim of this study was to assess the role of the VEGF -2578C/A, +936C/T, and -460T/C gene polymorphisms in the development of osteosarcoma. A total of 182 patients with osteosarcoma and 182 age- and gender-matched healthy controls were enrolled into our study during January 2011 and December 2013. Genotype frequencies of the VEGF -2578C/A and -460T/C alleles in controls were found to be within the parameters of Hardy-Weinberg equilibrium, but the genotype frequencies of +936C/T alleles were not. By conditional regression analysis, we detected a statistically significantly increased risk of osteosarcoma in patients with the AA genotype (OR = 1.97; 95%CI = 1.02-3.83) and the CA+AA genotype (OR = 1.57; 95%CI = 1.01-2.44) of -2578C/A when compared with CC genotype. Therefore, our study showed that the AA and CA+AA genotypes of the VEGF -2578C/A polymorphism might modify the risk of osteosarcoma in a Chinese population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26400284     DOI: 10.4238/2015.September.8.14

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  3 in total

1.  Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population.

Authors:  Qiang Xu; Zuofu Zhang; Weixue Sun; Baiqiang Hu
Journal:  Mamm Genome       Date:  2017-05-04       Impact factor: 2.957

2.  Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.

Authors:  Yuan-Yuan Hu; Xin-Ya Du; Ai-Ling Zhan; Lan Zhou; Qian Jiang; Yu-Ming Niu; Ming Shen
Journal:  Oncotarget       Date:  2016-07-26

3.  Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Authors:  Clara Benna; Andrea Simioni; Sandro Pasquali; Davide De Boni; Senthilkumar Rajendran; Giovanna Spiro; Chiara Colombo; Calogero Virgone; Steven G DuBois; Alessandro Gronchi; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Oncotarget       Date:  2018-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.